Combining Pharmacotherapy and Psychological Treatments for OCD

The Oxford Handbook of Obsessive Compulsive and Spectrum Disorders

Volumn , Issue , 2012, Pages

  Tolin, David F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Behavior therapy; Cognitive behavioral therapy; Combination therapy; Exposure and response prevention; Medications; Obsessive compulsive disorder; SSRI

Indexed keywords

EID: 84923269917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780195376210.013.0081     Document Type: Chapter

References (68)

1. Arnone, D., & Schifano, F. (2006). Psychedelics in psychiatry. British Journal of Psychiatry, 188, 88; author reply 89.
2. Baker, J. D., & Azorlosa, J. L. (1996). The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behavioral Neuroscience, 110(3), 618-620.
3. Beck, A. T., Emery, G., & Greenberg, R. L. (1985). Anxiety disorders and phobias: A cognitive perspective. New York: Basic Books.
4. Boje, K. M., Wong, G., & Skolnick, P. (1993). Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Research, 603(2), 207-214.
5. Bouton, M. E. (1993). Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychological Bulletin, 114(1), 80-99.
6. Busch, A. K., & Johnson, W. C. (1950). L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Diseases of the Nervous System, 11(8), 241-243.
7. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2 ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
8. Cottraux, J., Bouvard, M., Defayolle, M., & Messy, P. (1988). Validity and factorial structure study of the compulsive activity checklist. Behavior Therapy, 19, 45-53.
9. Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A. M., et al. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology, 5(1), 17-30.
10. Cottraux, J., Mollard, E., Bouvard, M., & Marks, I. (1993). Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Research, 49(1), 63-75.
11. Cox, J., & Westbrook, R. F. (1994). The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat. Quarterly Journal of Experimental Psychology B, 47(2), 187-210.
12. Davis, M. (2002). Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. The European Journal Of Neuroscience, 16(3), 395-398.
13. Davis, M., & Myers, K. M. (2002). The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biological Psychiatry, 52(10), 998-1007.
14. Delgado, P. L., & Moreno, F. A. (1998). Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. British Journal of Psychiatry (Suppl.)(35), 21-25.
15. Duncan, E. J., Szilagyi, S., Schwartz, M. P., Bugarski-Kirola, D., Kunzova, A., Negi, S., et al. (2004). Effects of Dcycloserine on negative symptoms in schizophrenia. Schizophrenia Research, 71(2-3), 239-248.
16. Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C., Schwartz, P., Hantsburger, G., et al. (1995). Evaluation of cycloserine in the treatment of Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology, 8(4), 226-230.
17. Fanselow, M. S., & LeDoux, J. E. (1999). Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. Neuron, 23(2), 229-232.
18. Foa, E. B., & Emmelkamp, P. M. (1983). Failures in behavior therapy. New York: Wiley.
19. Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99(1), 20-35.
20. Foa, E. B., Kozak, M. J., Steketee, G., & McCarthy, P. R. (1992). Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy. British Journal of Clinical Psychology, 31 (Pt 3), 279-292.
21. Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162(1), 151-161.
22. Glass, G. V., McGaw, B., & Smith, M. L. (1981). Meta-analysis in social research. London: Sage Publications.
23. Goff, D. C., Herz, L., Posever, T., Shih, V., Tsai, G., Henderson, D. C., et al. (2005). A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl), 179(1), 144-150.
24. Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., et al. (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry, 46(11), 1006-1011.
25. Goosens, K. A., & Maren, S. (2002). Long-term potentiation as a substrate for memory: evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning. Hippocampus, 12(5), 592-599.
26. Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., et al. (2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry, 63(6), 544-549.
27. Guy, W. (1976). Assessment manual for psychopharmacology. Washington, DC: U.S. Government Printing Office.
28. Hanes, K. R. (1996). Serotonin, psilocybin, and body dysmorphic disorder: a case report. Journal of Clinical Psychopharmacology, 16(2), 188-189.
29. Hofmann, S. G., Meuret, A. E., Smits, J. A., Simon, N. M., Pollack, M. H., Eisenmenger, K., et al. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63(3), 298-304.
30. Hohagen, F., Winkelmann, G., Rasche-Ruchle, H., Hand, I., Konig, A., Munchau, N., et al. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. British Journal of Psychiatry, 35, 71-78.
31. Holzinger, R. (1964). Lsd-25, a Tool in Psychotherapy. Journal of General Psychology, 71, 9-20.
32. Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology, 59(1), 12-19.
33. Kampman, M., Keijsers, G. P., Hoogduin, C. A., & Verbraak, M. J. (2002). Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatrica Scandinavica, 106(4), 314-319.
34. Koran, L. M., Hanna, G. L., Hollander, E., Nestadt, G., & Simpson, H. B. (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry, 164(7 Suppl), 5-53.
35. Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., et al. (2007). D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry, 62(8), 835-838.
36. Laake, K., & Oeksengaard, A. R. (2002). D-cycloserine for Alzheimer's disease. Cochrane Database of Systematic Reviews (2), CD003153.
37. Ledgerwood, L., Richardson, R., & Cranney, J. (2003). Effects of D-cycloserine on extinction of conditioned freezing. Behavioral Neuroscience, 117(2), 341-349.
38. Leonard, H. L., & Rapoport, J. L. (1987). Relief of obsessive-compulsive symptoms by LSD and psilocin. American Journal of Psychiatry, 144(9), 1239-1240.
39. Ludwig, A. M., & Levine, J. (1965). A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. American Journal of Psychotherapy, 19, 417-435.
40. March, J. S., Frances, A., Carpenter, D., & Kahn, D. A. (1997). The expert consensus guideline series: Treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 58 (Suppl. 4).
41. Marks, I. M., Stern, R. S., Mawson, D., Cobb, J., & McDonald, R. (1980). Clomipramine and exposure for obsessivecompulsive rituals: i. British Journal of Psychiatry, 136, 1-25.
42. Mechaneck, R., Feldstein, S., Dahlberg, C. C., & Jaffe, J. (1968). Experimental investigation of LSD as a psychotherapeutic adjunct. Comprehensive Psychiatry, 9(5), 490-498.
43. Moreno, F. A., & Delgado, P. L. (1997). Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry, 154(7), 1037-1038.
44. Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735-1740.
45. Multidisciplinary Association for Psychedelic Studies. (2008). LSD and psilocybin research Retrieved September 1, 2008, from http://www.maps.org/research/cluster/psilo-lsd/
46. Neill, J. R. (1987). "More than medical significance": LSD and American psychiatry 1953 to 1966. Journal of Psychoactive Drugs, 19(1), 39-45.
47. Neziroglu, F., Yaryura-Tobias, J. A., Walz, J., & McKay, D. (2000). The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 10(4), 295-306.
48. Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry, 63(12), 1118-1126.
49. Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., et al. (2010). Efficacy of dcycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biological Psychiatry, 67(4), 365-370.
50. Pediatric OCD Treatment Study Team. (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association, 292(16), 1969-1976.
51. Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., et al. (2004). Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry, 61(11), 1136-1144.
52. Rogan, M. T., Staubli, U. V., & LeDoux, J. E. (1997). Fear conditioning induces associative long-term potentiation in the amygdala. Nature, 390(6660), 604-607.
53. Rosenthal, R. (1991). Meta-analytic procedures for social research. London: Sage Publications.
54. Royer, S., & Pare, D. (2002). Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses. Neuroscience, 115(2), 455-462.
55. Santini, E., Muller, R. U., & Quirk, G. J. (2001). Consolidation of extinction learning involves transfer from NMDAindependent to NMDA-dependent memory. Journal of Neuroscience, 21(22), 9009-9017.
56. Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844-852.
57. Simpson, H. B., Gorfinkle, K. S., & Liebowitz, M. R. (1999). Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry, 60(9), 584-590.
58. Simpson, H. B., Liebowitz, M. R., Foa, E. B., Kozak, M. J., Schmidt, A. B., Rowan, V., et al. (2004). Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depression and Anxiety, 19(4), 225-233.
59. Soskin, R. A. (1973). The use of LSD in time-limited psychotherapy. Journal of Nervous and Mental Disease, 157(6), 410-419.
60. Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., et al. (2007). D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22(4), 230-237.
61. TenHave, T. R., Coyne, J., Salzer, M., & Katz, I. (2003). Research to improve the quality of care for depression:alternatives to the simple randomized clinical trial. General Hospital Psychiatry, 25(2), 115-123.
62. Tenneij, N. H., van Megen, H. J., Denys, D. A., & Westenberg, H. G. (2005). Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. Journal of Clinical Psychiatry, 66(9), 1169-1175.
63. Tolin, D. F., Maltby, N., Diefenbach, G. J., Hannan, S. E., & Worhunsky, P. (2004). Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: A wait-list-controlled open trial. Journal of Clinical Psychiatry, 65(7), 922-931.
64. Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2005). Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 72(2-3), 225-234.
65. van Balkom, A. J., de Haan, E., van Oppen, P., Spinhoven, P., Hoogduin, K. A., & van Dyck, R. (1998). Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. Journal of Nervous and Mental Disease, 186(8), 492-499.
66. Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. Journal of Neuroscience, 22(6), 2343-2351.
67. Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., et al. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry, 165(3), 335-341.
68. Williams, J. M. G., Watts, F. N., MacLeod, C., & Mathews, A. (1997). Cognitive psychology and emotional disorders (2nd ed.). New York: John Wiley & Sons.